In the outpatient clinic, many patients with stage I lung cancer ask the same question:
"Doctor, what do I need to do next?"
Behind that question lies a deeper worry —
if the risk is low, can I simply do nothing? If the risk is high, should we intervene right away?
In reality, this question is often harder to answer than "should we treat or not".
1One stage, different destinies
Two patients, both with stage I non-small cell lung cancer.
Their tumours are much the same size, the surgery went smoothly, and their recovery was uneventful.
They sit in front of the doctor with almost identical pathology reports.
Yet the doctor knows: their outcomes are likely to head in opposite directions.
The problem is that
the routine information available cannot tell the doctor clearly:
● Who is more likely to relapse?
● Who can be safely observed?
● Who needs intervention before it is due?
Medicine is never short of "answers"; what it lacks is that definitive dividing line. And patients with stage I disease are stranded in precisely this grey zone.
"Stage I" reads like a reassuring stamp: early, mild, controllable. Yet what patients are truly anxious about has never been the "now" — it is the "after", the part no one can predict.
"Regular check-ups" can sometimes sound like another way of saying: "leave the rest to time."
And before imaging detects anything, certain changes have already begun.
The risk is not absent; we simply have not seen it clearly yet.
That is precisely why, after surgery for the same stage I disease, some people come safely through five years while others relapse within six months.
The difference often lies not in the surgery itself, but in the biological code that has yet to be read accurately.
2Two choices, two risks
Without precise stratification tools, doctors are usually left with two paths:
Path one: conservative observation
Follow-up according to guidelines, relying on imaging and blood markers.
If the patient is genuinely low-risk, everyone is relieved.
But if the patient is in fact high-risk, the signal of relapse may have passed the optimal intervention window before it is ever noticed.
—— The most regrettable outcome is not having failed to see it, but having seen it too late.
Path two: early intervention
To be on the safe side, some patients are advised to undergo intensified monitoring or adjuvant therapy.
But if the patient is in fact low-risk, that means unnecessary side effects, financial burden and psychological pressure.
—— Treating low risk as high risk harms people too.
In the ambiguous territory of stage I,
whichever path is chosen, a price is paid in uncertainty.
And the doctor is the one who has to make that choice for the patient.
3Staging is a map, not an instruction manual
TNM staging matters greatly in clinical practice. Like a "map", it marks the location, size and extent of spread of the tumour — but it is not a "personal instruction manual".
Two patients both labelled stage I may have tumours that behave in completely different ways — what truly determines recurrence risk is the tumour's biological behaviour, not the stage itself.
In other words:
● Staging answers "where the problem is"
● Doctors care more about "what happens next"
What routine tools lack most is exactly this forward-looking judgement. That is also why two stage I patients may end up with completely different outcomes.
4From "weighing up" to "judging"
What we need is evidence that sees through appearances:
has the patient's "recurrence-drive signal" already switched on? How strong is it?
That determines the nature of the decision — moving from a vague "weighing up" to a precise "judgement".
And the outcome is clear:
● Those at low risk are spared unnecessary intervention and anxiety
● Those at high risk gain a precious head start on intervention.
This is not about adding more treatment; it is about grounding every decision on solid evidence.
5When medicine looks towards a future that "may yet happen"
As medicine's gaze shifts from "what has happened" to "what may happen",
the logic of managing stage I disease after surgery is rebuilt along with it:
From relying on time and experience in a calculated gamble,
towards precise stratification based on biological characteristics.
Perhaps before long, when a patient asks again:
"Doctor, what should I do next?"
The answer will come without hesitation: "Now, we can already see the answer that belongs to you."
